Home > Online Clinic News > Belviq Criticism on US Debut

Latest News

by Robert MacKay, Sunday, June 16, 2013 | Categories: Lorcaserin

At the beginning of last month we announced that the new weight loss pill named Belviq©, from Arena Pharmaceuticals, was going to be able to be prescribed soon to obese and overweight patients in the United States. Since then, many criticisms have accompanied its debut. One in particular was made by Consumer Reports.

The article gives two main reasons as to why Consumer Reports do not recommend taking the pill. First of all, they claim that studies show that patients who take it for a year are expected to lose only a slight percentage of their body weight (from 3 to 3.7%). Second, the side effects might be quite severe.

Another article, published in the Los Angeles Times, also heavily criticises the drug, saying that patients who decide to take it must take it for their whole life in order to keep the weight off. They also mention that long-term side effects are not predictable and that quick-fix pills are simply not effective at resolving a complex problem such as obesity.

While some of the criticisms may be valid, it is really up the doctor and patient to decide what is appropriate. It is true that some patients do not lose very much weight – this is the case with other weight loss medications as well. The low responders (as we call them) can usually be identified early (within a couple of months) and they should probably stop being prescribed further courses as the risk of side effects may outweigh any potential benefit from the marginal weight loss.

We have to concede that the average weight loss is not impressive and it probably should only continue being prescribed on a patient by patient basis if they are losing reasonable levels of weight. 3% over the course of 12 months is really not sufficient to justify continuing prescribing.

Belviq contains Lorcaserin as the active ingredient. The application for a license to have Lorcaserin prescribed in the EU was recently withdrawn as Arena Pharmaceuticals was not going to be in a position to answer all of the outstanding questions with the European Medicines Agency. We would expect a further application to be made in due course.

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more Close